{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:01:25Z","timestamp":1787032885605,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,18]]},"DOI":"10.7759\/cureus.58516","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T06:42:34Z","timestamp":1713422554000},"source":"Crossref","is-referenced-by-count":4,"title":["Impulse Control Disorders in Southern Iraqi Patients Medicated With Cabergoline for Prolactinoma"],"prefix":"10.7759","author":[{"given":"Mohammad M","family":"Mohammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haider  A","family":"Alidrisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas A","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam MP","year":"2006","unstructured":"Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006, 27:485-534. 10.1210\/er.2005-9998","journal-title":"Endocr Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of Prolactinomas: the old and the new","volume":"33","author":"Chanson P","year":"2019","unstructured":"Chanson P, Maiter D. The epidemiology, diagnosis and treatment of Prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab. 2019, 33:101290. 10.1016\/j.beem.2019.101290","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2021.104080","article-title":"Prolactinomas","volume":"50","author":"Wildemberg LE","year":"2021","unstructured":"Wildemberg LE, Fialho C, Gadelha MR. Prolactinomas. Presse Med. 2021, 50:104080. 10.1016\/j.lpm.2021.104080","journal-title":"Presse Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.13632.2","article-title":"Spectrum of pituitary disorders: a retrospective study from Basrah, Iraq","volume":"7","author":"Mansour AA","year":"2018","unstructured":"Mansour AA, Alhamza AH, Almomin AM, et al.. Spectrum of pituitary disorders: a retrospective study from Basrah, Iraq. F1000Res. 2018, 7:430. 10.12688\/f1000research.13632.2","journal-title":"F1000Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva FF","year":"2006","unstructured":"Casanueva FF, Molitch ME, Schlechte JA, et al.. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006, 65:265-273. 10.1111\/j.1365-2265.2006.02562.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-56015-1_223-1","article-title":"Cabergoline in the treatment of Parkinson\u2019s disease","author":"Tsuboi T","year":"2019","unstructured":"Tsuboi T, Watanabe H, Katsuno M, Sobue G. Cabergoline in the treatment of Parkinson\u2019s disease. NeuroPsychopharmacotherapy. Springer, Cham, 2019. 1-10. 10.1007\/978-3-319-56015-1_223-1"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-13-2-220","article-title":"Dopamine agonists and pituitary tumor shrinkage","volume":"13","author":"Bevan JS","year":"1992","unstructured":"Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev. 1992, 13:220-240. 10.1210\/edrv-13-2-220","journal-title":"Endocr Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.82.3.3822","article-title":"Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment","volume":"82","author":"Colao A","year":"1997","unstructured":"Colao A, Di Sarno A, Sarnacchiaro F, et al.. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab. 1997, 82:876-883. 10.1210\/jcem.82.3.3822","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2011.04.055","article-title":"Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease","volume":"104","author":"Ahlskog JE","year":"2011","unstructured":"Ahlskog JE. Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease. Physiol Behav. 2011, 104:168-172. 10.1016\/j.physbeh.2011.04.055","journal-title":"Physiol Behav"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200009)15:5<869::AID-MDS1016>3.0.CO;2-I","article-title":"Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?","volume":"15","author":"Molina JA","year":"2000","unstructured":"Molina JA, S\u00e1inz\u2010Artiga MJ, Fraile A, et al.. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?. Mov Disord. 2000, 15:869-872. 10.1002\/1531-8257(200009)15:5&lt;869::AID-MDS1016&gt;3.0.CO;2-I","journal-title":"Mov Disord"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3182281b2f","article-title":"Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas","volume":"34","author":"Martinkova J","year":"2011","unstructured":"Martinkova J, Trejbalova L, Sasikova M, Benetin J, Valkovic P. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clin Neuropharmacol. 2011, 34:179-181. 10.1097\/WNF.0b013e3182281b2f","journal-title":"Clin Neuropharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2011.00001","article-title":"Impulse control disorders: updated review of clinical characteristics and pharmacological management","volume":"2","author":"Schreiber L","year":"2011","unstructured":"Schreiber L, Odlaug BL, Grant JE. Impulse control disorders: updated review of clinical characteristics and pharmacological management. Front Psychiatry. 2011, 2:1. 10.3389\/fpsyt.2011.00001","journal-title":"Front Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22571","article-title":"Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease","volume":"24","author":"Weintraub D","year":"2009","unstructured":"Weintraub D, Hoops S, Shea JA, et al.. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord. 2009, 24:1461-1467. 10.1002\/mds.22571","journal-title":"Mov Disord"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1556\/2006.4.2015.041","article-title":"How should severity be determined for the DSM-5 proposed classification of hypersexual disorder?","volume":"4","author":"Reid RC","year":"2015","unstructured":"Reid RC. How should severity be determined for the DSM-5 proposed classification of hypersexual disorder?. J Behav Addict. 2015, 4:221-225. 10.1556\/2006.4.2015.041","journal-title":"J Behav Addict"},{"key":"ref15","unstructured":"Table 1, DSM-IV and DSM-5 diagnostic criteria for binge-eating disorder - Management and Outcomes of Binge-Eating Disorder - NCBI Bookshelf. (2015). https.\/\/www.ncbi.nlm.nih.gov\/books\/NBK338301\/table\/introduction.t1\/."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1556\/2006.2021.00013","article-title":"Proposed diagnostic criteria for compulsive buying-shopping disorder: a Delphi expert consensus study","volume":"10","author":"M\u00fcller A","year":"2021","unstructured":"M\u00fcller A, Laskowski NM, Trotzke P, et al.. Proposed diagnostic criteria for compulsive buying-shopping disorder: a Delphi expert consensus study. J Behav Addict. 2021, 10:208-222. 10.1556\/2006.2021.00013","journal-title":"J Behav Addict"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz076","article-title":"Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors","volume":"105","author":"De Sousa SM","year":"2020","unstructured":"De Sousa SM, Baranoff J, Rushworth RL, et al.. Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors. J Clin Endocrinol Metab. 2020, 105:e108-e118. 10.1210\/clinem\/dgz076","journal-title":"J Clin Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02202","article-title":"Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study","volume":"104","author":"Dogansen SC","year":"2019","unstructured":"Dogansen SC, Cikrikcili U, Oruk G, et al.. Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study. J Clin Endocrinol Metab. 2019, 104:2527-2534. 10.1210\/jc.2018-02202","journal-title":"J Clin Endocrinol Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/WNN.0000000000000320","article-title":"Effect of dopaminergic therapy on impulse control disorders in patients with a prolactinoma","volume":"36","author":"Varan EO","year":"2023","unstructured":"Varan EO, Gurvit H. Effect of dopaminergic therapy on impulse control disorders in patients with a prolactinoma. Cogn Behav Neurol. 2023, 36:1-8. 10.1097\/WNN.0000000000000320","journal-title":"Cogn Behav Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12375","article-title":"Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study","volume":"80","author":"Bancos I","year":"2014","unstructured":"Bancos I, Nannenga MR, Bostwick JM, Silber MH, Erickson D, Nippoldt TB. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol (Oxf). 2014, 80:863-868. 10.1111\/cen.12375","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2023.102910","article-title":"Impulse control disorders in patients with pituitary tumors treated with dopamine agonists: a systematic review","volume":"54","author":"Hamblin R","year":"2023","unstructured":"Hamblin R, Karavitaki N. Impulse control disorders in patients with pituitary tumors treated with dopamine agonists: a systematic review. Arch Med Res. 2023, 54:102910. 10.1016\/j.arcmed.2023.102910","journal-title":"Arch Med Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.05.014","article-title":"Impulse control and related disorders in Mexican Parkinson's disease patients","volume":"20","author":"Rodr\u00edguez-Violante M","year":"2014","unstructured":"Rodr\u00edguez-Violante M, Gonz\u00e1lez-Latapi P, Cervantes-Arriaga A, Camacho-Ordo\u00f1ez A, Weintraub D. Impulse control and related disorders in Mexican Parkinson's disease patients. Parkinsonism Relat Disord. 2014, 20:907-910. 10.1016\/j.parkreldis.2014.05.014","journal-title":"Parkinsonism Relat Disord"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2016.06.005","article-title":"Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients","volume":"30","author":"Krishnamoorthy S","year":"2016","unstructured":"Krishnamoorthy S, Rajan R, Banerjee M, et al.. Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients. Parkinsonism Relat Disord. 2016, 30:13-17. 10.1016\/j.parkreldis.2016.06.005","journal-title":"Parkinsonism Relat Disord"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac718","article-title":"A genetic assessment of dopamine agonist-induced impulse control disorder in patients with prolactinoma","volume":"108","author":"Sahin S","year":"2023","unstructured":"Sahin S, Sudutan T, Kavla Y, et al.. A genetic assessment of dopamine agonist-induced impulse control disorder in patients with prolactinoma. J Clin Endocrinol Metab. 2023, 108:e275-e282. 10.1210\/clinem\/dgac718","journal-title":"J Clin Endocrinol Metab"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-016-1088-1","article-title":"Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists","volume":"55","author":"De Sousa SM","year":"2017","unstructured":"De Sousa SM, Chapman IM, Falhammar H, Torpy DJ. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists. Endocrine. 2017, 55:618-624. 10.1007\/s12020-016-1088-1","journal-title":"Endocrine"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1530\/EO-21-0038","article-title":"Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?","volume":"2","author":"De Sousa SM","year":"2022","unstructured":"De Sousa SM. Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?. Endocr Oncol. 2022, 2:R31-R50. 10.1530\/EO-21-0038","journal-title":"Endocr Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2012.10.002","article-title":"Dopamine agonist-induced impulse control disorders in a patient with prolactinoma","volume":"54","author":"Almanzar S","year":"2013","unstructured":"Almanzar S, Zapata-Vega MI, Raya JA. Dopamine agonist-induced impulse control disorders in a patient with prolactinoma. Psychosomatics. 2013, 54:387-391. 10.1016\/j.psym.2012.10.002","journal-title":"Psychosomatics"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.86.P247","article-title":"Surgical management of prolactinomas in patients with dopamine agonist-associated impulse control disorders or who are deemed at \u2018high risk\u2019","volume":"86","author":"Yu AT","year":"2022","unstructured":"Yu AT, Wernig F, Meeran K, et al.. Surgical management of prolactinomas in patients with dopamine agonist-associated impulse control disorders or who are deemed at \u2018high risk\u2019. Endocr Abstr. 2022, 86:247. 10.1530\/endoabs.86.P247","journal-title":"Endocr Abstr"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/245608-impulse-control-disorders-in-southern-iraqi-patients-medicated-with-cabergoline-for-prolactinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T06:42:39Z","timestamp":1713422559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/245608-impulse-control-disorders-in-southern-iraqi-patients-medicated-with-cabergoline-for-prolactinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.58516","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,18]]}}}